EUROPEAN DISTRIBUTION PARTNERSHIP WITH LINDE

May 9th, 2018

 

Subject:  European Distribution Partnership with Linde

 

(Abingdon, United Kingdom) NeuroproteXeon announced today that they have completed a distribution agreement with Linde AG (Lin.de) for XENEX™ (xenon by inhalation) for Post Cardiac Arrest Syndrome (”PCAS”) for the European Union plus United Kingdom, Switzerland, Norway and Iceland.

            The agreement includes a multi-tiered royalty and 23 million euros in milestone payments.  The two key milestone payments are on approval for PCAS from the European Medicines Agency (“EMA”) and when Linde reaches cumulative sales of 100 million euros – provided this occurs in the first four years following approval.

            Bill Burns, CEO of NeuroproteXeon, was elated with the agreement. “When we started the Company we believed the nitric oxide business model established by Linde, and employed by Mallinckrodt in North America, was going to be our go to market strategy.   To be able to partner with both these companies established a terrific platform for mutual success.”

            Urmi Prasad Richardson, Global Head of Healthcare in the Centre of Excellence, noted, “This partnership marks the continued commitment Linde has to Healthcare innovation through development of new technologies, and therapeutic uses of medical gas.  It is gratifying to be developing a product that combines the potential to save lives with significant commercial viability. Linde’s portfolio continues to evolve to meet the demands of the market and our customers.”

 

About NeuroproteXeon

NeuroproteXeon, Inc. is a clinical-stage pharmaceutical/device company developing xenon to improve functional capabilities and survival in patients with Post-Cardiac Arrest Syndrome (“PCAS”).  The Company has a license agreement with Mallinckrodt LLC (NYSE:MNK) for the sale and distribution of xenon gas for inhalation in North America, Australia and Japan upon approval of the drug in those markets.

 

About Linde Healthcare

Linde Healthcare is a global leader specializing along an integrated respiratory care path. It combines pharmaceutical gases, medical devices, services and clinical care into solutions with the patient in mind. Its products and services make a difference in the lives of its patients and to its healthcare partners in the care continuum from hospital to home. A global business unit of The Linde Group, it is present in over 60 countries and generated revenues of EUR 3.361bn in 2017.

For more information, visit Linde Healthcare online at www.linde-healthcare.com

 

About The Linde Group

In the 2017 financial year, The Linde Group generated revenue of EUR 17.113 bn, making it one of the leading gases and engineering companies in the world, with approximately 58,000 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term profitable growth and focuses on the expansion of its international business, with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.

For more information, see The Linde Group online at www.linde.com

 

Contacts:

Linde

Peter Senior

Global Healthcare Portfolio Coordinator

peter.senior@linde.com

Phone: +49.89.7446-2340

 

NeuroproteXeon:

Carol Burns

Communications Director

carol.burns.op@neuroprotexeon.com

Phone: +1 716-332-7200 ext: 155

 

 

 

DISCLAIMER – IMPORTANT

ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO WHICH THIS GATEPOST GIVES ACCESS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY NEUROPROTEXEON LIMITED (“NPXe”) IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.
THE MATERIALS TO WHICH THIS GATEPOST GIVE ACCESS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN OR RESIDENT IN (OR ORGANISED OR INCORPORATED UNDER THE LAWS OF) THE UNITED STATES OR U.S. PERSONS (AS SUCH TERM IS DEFINED IN REGULATION S (“REGULATION S”) UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)), WHEREVER LOCATED, OR PERSONS RESIDENT OR LOCATED IN AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE EXTENSION OF AVAILABILITY OF THE MATERIALS TO WHICH YOU ARE SEEKING ACCESS WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan, or in any jurisdiction in which such offers or sales are unlawful (the “Excluded Territories”) or to U.S. Persons (as such term is defined in Regulation S), wherever located. Any securities issued in connection with an offering have not been and will not be registered under the Securities Act or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United States, Australia, Canada or Japan. Accordingly, unless an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States.
The materials are only addressed to and directed at persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and any amendments thereto including Directive 2010/73/EU to the extent implemented in the relevant EEA member state) and any relevant implementing measure in the relevant member state of the EEA (“Qualified Investors”). In addition, in the United Kingdom, the materials are being distributed only to, and are directed at Qualified Investors (as defined above) who are (a) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (b) high net worth entities, and other persons falling within Article 49(2)(a) to (d) of the Order to whom they may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which these materials relates are available only to Relevant Persons in the United Kingdom and Qualified Investors in any member state of the EEA other than the United Kingdom, and will only be engaged with such persons.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. These materials must not be released or otherwise forwarded, distributed or sent to U.S. Persons or otherwise in or into the United States, Australia, Canada, Japan, or any jurisdiction in which such offers or sales are unlawful. Persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them to U.S Persons or otherwise in, into or from the United States, Australia, Canada or Japan.
Confirmation of understanding and acceptance of disclaimer
I warrant that I am not a resident of, or located in, the United States, Australia, Canada or Japan or any other jurisdiction where accessing these materials is unlawful, nor a U.S. Person, and I agree that I will not transmit or otherwise send any materials contained in this website to any U.S Person or any other person in the United States, Australia, Canada, Japan or any other jurisdiction where to do so would breach applicable local law or regulation.
I have read and understood the disclaimer set out above. I understand that it may affect my rights and I agree to be bound by its terms. I confirm that I am permitted to proceed to electronic versions of the materials.
NeuroproteXeon does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.
[I ACCEPT] [DON’T ACCEPT]